Illuminate PD1/PD-L1 Interactions
Explore immune checkpoint activation in situ
Introducing Naveni™ PD1/PD-L1 Atto 647N
Unlocking the potential of immune checkpoint inhibition therapy calls for precise patient stratification 1-3. While PD-L1 is a commonly used biomarker, its correlation with immunotherapy outcomes isn’t always linear3. Addressing this challenge, Navinci expands its portfolio to unravel PD1 signaling, introducing the groundbreaking fluorescent assay, Naveni™ PD1/PD-L1 Atto 647N.
With Naveni™ PD1/PD-L1 Atto 647N, you can now achieve a comprehensive visualization of the tumor microenvironment through co-staining. Illuminate PD1/PD-L1 interactions like never before and gain a deeper understanding of immune checkpoint activation.
If you prefer to detect PD1/PD-L1 using bright-field, Navinci has you covered with our chromogenic assays. Choose from their range of assays to suit your specific research needs and explore the PD1 signaling pathway.
The Naveni PD1/PD-L1 kits are based on Navinci’s proprietary NaveniTM Proximity Ligation Technology. The kits include two Navenibodies conjugated to proprietary oligo arms (depicted as orange antibodies in the illustration).
Only if the Navenibodies are in close proximity will they generate a rolling circle amplification reaction, leading to a strong and distinct dot. Naveni PD1/PD-L1 Atto647N is compatible with IF co-staining.
Visualize PD1/PD-L1 interaction in the tumor microenvironment
Images show Non-small-cell lung cancer samples positive and negative for the PD1/PD-L1 interaction (magenta). Tumor tissue visualized by cytokeratin co-staining (yellow).
Data of PD1/PD-L1 interaction staining in tumor tissues
PD1/PD-L1 Interaction Products
Visualize the interaction of PD1 and PD-L1 in situ. The kit includes primary Navenibodies specific to PD1 and PD-L1, and all other reagents needed to run the assay. Chromogenic detection and bright-field read-out.
Phosphorylated PD1 Products
Visualize phosphorylated PD1 in situ. The kit includes primary Navenibodies specific to phosphorylated PD1 and all other reagents needed to run the assay. Chromogenic detection and bright-field read-out.
Naveni pY PD1 HRP
Naveni pY PD1 AP
1.Pu Y, Ji Q. Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression. Front Immunol. 2022 May 3;13:874589.
2.Robert C, A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020; 11: 3801
3.Sánchez-Magraner L, et al. High PD-1/PD-L1 Checkpoint Interaction Infers Tumor Selection and Therapeutic Sensitivity to Anti-PD-1/PD-L1 Treatment. Cancer Res. 2020 Oct 1;80(19):4244-4257